To examine the impact of dasatinib on the CD8+ T-cell repertoire in CML patients, we administered 100 mg of the drug and compared blood samples drawn at baseline with blood samples drawn after 1 hour. This evidence concerns the gene CD8A and chronic myelogenous leukemia, BCR-ABL1 positive.